TWI907333B - 用於治療cns病症之組合物及方法 - Google Patents

用於治療cns病症之組合物及方法

Info

Publication number
TWI907333B
TWI907333B TW107146684A TW107146684A TWI907333B TW I907333 B TWI907333 B TW I907333B TW 107146684 A TW107146684 A TW 107146684A TW 107146684 A TW107146684 A TW 107146684A TW I907333 B TWI907333 B TW I907333B
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
group
alkyl
compound
Prior art date
Application number
TW107146684A
Other languages
English (en)
Chinese (zh)
Other versions
TW201938172A (zh
Inventor
艾伯特 J 羅比喬德
法藍西司科 G 薩突羅
佩拉杜 馬利亞 耶稣 巴蘭可
丹尼爾 拉
柏伊德 L 哈里森
Original Assignee
美商賽吉醫療有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65234664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI907333(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商賽吉醫療有限責任公司 filed Critical 美商賽吉醫療有限責任公司
Publication of TW201938172A publication Critical patent/TW201938172A/zh
Application granted granted Critical
Publication of TWI907333B publication Critical patent/TWI907333B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/19—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
    • C07C49/507—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic
    • C07C49/513—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/004—Expansion of ring B by one atom, e.g. B homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/006—Expansion of ring C by one atom, e.g. C homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW107146684A 2017-12-22 2018-12-22 用於治療cns病症之組合物及方法 TWI907333B (zh)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201762610067P 2017-12-22 2017-12-22
US62/610,067 2017-12-22
US201762611977P 2017-12-29 2017-12-29
US201762612164P 2017-12-29 2017-12-29
US201762612067P 2017-12-29 2017-12-29
US201762612070P 2017-12-29 2017-12-29
US62/612,067 2017-12-29
US62/611,977 2017-12-29
US62/612,070 2017-12-29
US62/612,164 2017-12-29
US201862765164P 2018-08-17 2018-08-17
US62/765,164 2018-08-17
US201862728499P 2018-09-07 2018-09-07
US62/728,499 2018-09-07
US201862737559P 2018-09-27 2018-09-27
US62/737,559 2018-09-27
US201862754977P 2018-11-02 2018-11-02
US62/754,977 2018-11-02

Publications (2)

Publication Number Publication Date
TW201938172A TW201938172A (zh) 2019-10-01
TWI907333B true TWI907333B (zh) 2025-12-11

Family

ID=65234664

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107146684A TWI907333B (zh) 2017-12-22 2018-12-22 用於治療cns病症之組合物及方法

Country Status (14)

Country Link
US (2) US20220315621A1 (https=)
EP (1) EP3728285B1 (https=)
JP (3) JP2021506904A (https=)
KR (1) KR20200104349A (https=)
CN (3) CN118085004A (https=)
AR (1) AR114044A1 (https=)
AU (2) AU2018392093B2 (https=)
BR (1) BR112020012761A2 (https=)
CA (1) CA3086189A1 (https=)
IL (2) IL275506A (https=)
MA (1) MA51316A (https=)
MX (3) MX2020006608A (https=)
TW (1) TWI907333B (https=)
WO (1) WO2019126761A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
BR112020012761A2 (pt) 2017-12-22 2021-02-17 Sage Therapeutics, Inc. composições e métodos para o tratamento de distúrbios do snc
TW201930269A (zh) 2018-01-12 2019-08-01 美商賽吉醫療公司 用於治療cns病症之組合物及方法
EP3750909B1 (en) * 2018-02-11 2025-03-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
EP4321519B1 (en) 2018-10-12 2026-04-08 Sage Therapeutics, LLC Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
KR20250174100A (ko) 2018-12-05 2025-12-11 세이지 테라퓨틱스, 인크. 신경활성 스테로이드 및 이의 사용 방법
CN115651054B (zh) * 2019-01-08 2024-06-21 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
JP7754725B2 (ja) * 2019-06-27 2025-10-15 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法
CN114729000A (zh) * 2019-06-27 2022-07-08 萨奇治疗股份有限公司 用于治疗cns病症的化合物
CA3143509A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
WO2025016311A1 (zh) * 2023-07-14 2025-01-23 成都康弘药业集团股份有限公司 一种甾体类化合物的晶型及其用途
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1494097A (en) * 1973-11-30 1977-12-07 Schering Ag D-homo-20-keto-pregnanes
GB1538869A (en) * 1974-12-23 1979-01-24 Schering Ag D-homo-20-keto-pregnanes and process for their manufacture
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
WO2014169833A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
DE2445161A1 (de) * 1974-09-19 1976-04-01 Schering Ag D-homo-20-ketopregnane ii
US5028631A (en) 1987-11-25 1991-07-02 Schwartz Arthur G Homoandrostan-17-one and homoandrosten-17-ones
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CN1067976C (zh) 1994-12-03 2001-07-04 东国制药株式会社 积雪草酸衍生物及其制备方法和包含该衍生物的皮科制剂
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
CN117024501A (zh) * 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
BR112020012761A2 (pt) 2017-12-22 2021-02-17 Sage Therapeutics, Inc. composições e métodos para o tratamento de distúrbios do snc
CN115651054B (zh) 2019-01-08 2024-06-21 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
JP7754725B2 (ja) 2019-06-27 2025-10-15 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1494097A (en) * 1973-11-30 1977-12-07 Schering Ag D-homo-20-keto-pregnanes
GB1538869A (en) * 1974-12-23 1979-01-24 Schering Ag D-homo-20-keto-pregnanes and process for their manufacture
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
WO2014169833A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
網路文獻 ITOH, S. ET AL, On the Acid-Catalyzed D-Homoannulation of Pregnanetriol 20-Sulfate and Its C-20 Isomeric Sulfate, CHEMICAL & PHARMACEUTICAL BULLETIN, (1994), 42(9), 1736-1744
網路文獻 PHILLIPPS G H ET AL, "Water-soluble steroidal anaesthetics" JOURNAL OF STEROID BIOCHEMISTRY, PERGAMON PRESS PLC, GB (19790701), vol. 11, no. 1,pages 79- 86;網路文獻 ITOH, S. ET AL, On the Acid-Catalyzed D-Homoannulation of Pregnanetriol 20-Sulfate and It *

Also Published As

Publication number Publication date
RU2020123930A3 (https=) 2022-02-04
CN111741965A (zh) 2020-10-02
AU2018392093B2 (en) 2024-02-01
RU2020123930A (ru) 2022-01-26
CN118085004A (zh) 2024-05-28
JP2023119042A (ja) 2023-08-25
CN118772223A (zh) 2024-10-15
AU2023285947A1 (en) 2024-01-25
TW201938172A (zh) 2019-10-01
US20220315621A1 (en) 2022-10-06
EP3728285B1 (en) 2026-04-08
IL323780A (en) 2025-12-01
MX2023002004A (es) 2023-02-27
EP3728285A1 (en) 2020-10-28
US20250171492A1 (en) 2025-05-29
CN111741965B (zh) 2024-06-25
JP2025078783A (ja) 2025-05-20
JP7689160B2 (ja) 2025-06-05
JP2021506904A (ja) 2021-02-22
CA3086189A1 (en) 2019-06-27
AR114044A1 (es) 2020-07-15
BR112020012761A2 (pt) 2021-02-17
IL275506A (en) 2020-08-31
MX2020006608A (es) 2020-11-06
WO2019126761A1 (en) 2019-06-27
MX2023002006A (es) 2023-02-27
MA51316A (fr) 2020-10-28
AU2018392093A1 (en) 2020-07-09
KR20200104349A (ko) 2020-09-03

Similar Documents

Publication Publication Date Title
TWI907333B (zh) 用於治療cns病症之組合物及方法
JP7611186B2 (ja) Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
TWI835765B (zh) 用於治療cns病症之組合物及方法
JP2023145726A (ja) ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP7671244B2 (ja) Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
JP2024096347A (ja) ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
RU2799448C2 (ru) Композиции и способы лечения заболеваний центральной нервной системы
RU2810331C2 (ru) Композиции и способы лечения заболеваний центральной нервной системы
TW202608452A (zh) 用於治療cns病症之組合物及方法
CN116685596A (zh) 用于治疗cns病症的组合物和方法
HK40040285A (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
HK40040285B (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders